Abstract |
A 73-year-old man with diffuse large cell lymphoma was treated with noncross resistant alternating combination chemotherapy of CHOP and BEMP, consisting of cyclophosphamide (1,000 mg/body, i.v., day 1), doxorubicin (60 mg/body, i.v., day 1), vincristine (2 mg/body, i.v., day 1), prednisolone (100 mg/body, p.o., day 1-5), bleomycin (30 mg/body, i.v., day 22), etoposide (80 mg/body, i.v., day 22-24), mitoxantrone (6 mg/body, i.v., day 22), and procarbazine (100 mg/body, p.o., day 22-26). Following the three courses' administration of CHOP and BEMP, complete remission was obtained with a remission duration of over ten months. Leukocytopenia was a dose-limiting factor. It is concluded that noncross resistant alternating combination chemotherapy of CHOP and BEMP is effective for diffuse large cell lymphoma.
|
Authors | T Itoh, Y Sakata, H Suzuki, N Sugimoto, N Sohma, T Kishibe, S Higuchi, Y Seino |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 19
Issue 2
Pg. 241-4
(Feb 1992)
ISSN: 0385-0684 [Print] Japan |
PMID | 1371049
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Bleomycin
- Procarbazine
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Mitoxantrone
- Prednisone
|
Topics |
- Administration, Oral
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Humans
- Infusions, Intravenous
- Lymphoma, Large B-Cell, Diffuse
(drug therapy)
- Male
- Mitoxantrone
(administration & dosage)
- Prednisone
(administration & dosage)
- Procarbazine
(administration & dosage)
- Remission Induction
- Vincristine
(administration & dosage)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|